<DOC>
	<DOCNO>NCT01896609</DOCNO>
	<brief_summary>A single Center , Prospective Phase IV , Open-Label , Controlled , Randomized Trial compare efficacy , safety , tolerability Quadritherapy regimen ( Reiferon Retard® , Ribavirin , Nitazoxanide Alfacalcidol ( Bon-One ® ) versus Triple therapy regimen ( Reiferon Retard® , Ribavirin Nitazoxanide ) versus standard care regimen ( Reiferon Retard® Ribavirin ) treatment Naïve chronic hepatitis C among Egyptian population . Effectiveness evaluate base Sustained Virological Response ( SVR ) . PRIMARY OBJECTIVE ( S ) : The primary objective trial follow : - To compare efficacy three treatment arm naïve Chronic Hepatitis C Virus ( HCV ) genotype 4 patient evaluate sustained virological response ( SVR ) week 60 ( 3 month end treatment period ) - Identify optimum treatment protocol HCV genotype 4 respect use combination medication - Whether add vitamin D , potent immunomodulator , could improve viral response . STUDY DESIGN : This phase IV , single center , open label , randomize ( 1:1:1 ) control study . NUMBER OF EVALUABLE SUBJECTS : 300 NUMBER OF CENTER/S : 1 Country : Egypt DURATION OF THE STUDY : 94 week TREATMENT : randomize 1:1:1 ratio 3 Arms SUBJECT POPULATION : male female subject assess BMI le 35 , age 20 50 year . Subjects diagnose Naïve Chronic Hepatitis C genotype 4 patient compensate liver disease assess hematological biochemical test . - DURATION OF THE STUDY : 94 week follow : Estimated Enrollment Duration : 16 week Collection last Case Report Form ( CRF ) : 2 week Last patient . Queries Resolution : 4 week Collection last CRF . Database lock plan date : 2 week Quires resolution . Final Study Report : 8 week Database lock . Estimated duration subject participation : 62 week follow ; - Screening period per subject = 2 week - Treatment phase per subject = 48 week - Follow-up phase per subject = 12 week N.B : Each patient receive medication Maximum 48 week his/her Polymerase Chain Reaction ( PCR ) -ve week 12 24 , his/her PCR +ve week 12 week 24 treatment stop .</brief_summary>
	<brief_title>Trial Comparing Efficacy , Tolerability Safety Between Three Arms Treatment HCV Egyptian Population</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Nitazoxanide</mesh_term>
	<mesh_term>Complement Factor H</mesh_term>
	<criteria>1 . The subject sign date write informed consent form ( ICF ) prior studyrelated activity , include discontinuation prohibit medication . 2 . If subject male sexually active , eligible enter participate study partner ( ) meet criterion outline 2a partner ( ) use one method birth control outline 2b . If subject female , eligible enter participate study meet follow criterion : 1 . Nonchildbearing potential ( i.e. , physiologically incapable become pregnant , include female postmenopausal ; purpose study , postmenopausal define 1 year without menses ) ; 2 . Childbearing potential , negative serum pregnancy test screening . 3 . The subject age 20 50 , inclusive time screen visit . 4 . The subject ambulatory outpatient . Ambulatory define depend exclusively wheelchair mobility . Nursing home subject may enrol provide ambulatory . Subjects spinal cord injury result paraplegia may enrol . 5 . The subject diagnose Hepatitis C genotype 4 . 6 . Subjects treatment Naive 7 . Male female subject BMI ≤ 35 . 8 . Compensated liver disease follow minimum hematological biochemical criterion : 1 . Hemoglobin &gt; 12 g/dl male , &gt; 11 g/dl female . 2 . White blood cell count ( WBC ) &gt; 3,000 /mm3 Absolute Neutrophilic count ( ANC 1000 ) 3 . Platelets &gt; 80,000/mm3 4 . Prothrombin time le 4 second upper limit normal ( ULN ) . 5 . Serum albumin &gt; 3.5mg/dl 6 . Normal Bilirubin level ( except Gilbert 's syndrome indirect Bilirubin &lt; 3mg/dl ) 7 . Histological diagnosis chronic hepatitis Fibroscan ( fibrosis assessment ) . 8 . Normal fast blood glucose level within 20 % ULN nondiabetic patient . If history diabetes , hemoglobin A1C &lt; 8.5 % ( evidence good glucose control recent month ) . 9 . Serum Creatinine within normal limit . 10 . Thyroid Stimulating Hormone ( TSH ) within normal limit test lab . Patients require medication maintain TSH eligible fulfil inclusion exclusion criterion . 11 . Alpha Fetoprotein within normal range obtain one year prior entry study . Results upper limit normal le 100 unit require follow : 1 . Alpha Fetoprotein obtain within 3 month entry . 2 . Abdominal Ultrasound within 3 month entry negative evidence hepatocellular carcinoma . 3 . If Alpha Fetoprotein 100 unit CT scan abdomen negative evidence hepatocellular carcinoma require . 12 . Patients must serum hepatitis B surface antigen ( HBsAg ) negative . 13 . Negative Antinuclear Antibodies ( ANA ) titer &lt; 1:160 14 . Serum positive antiHCV antibody HCVRNA . 15 . Abdominal Ultrasound obtain within one year prior entry study 16 . Electrocardiogram men age &gt; 40 year . 17 . Normal urine analysis . 18 . Normal fundus exam . 19 . Serum Schistosoma antibody test , positive &gt; 1/80 , rectal biopsy require . If rectal biopsy positive living Schistosomal egg , treatment Active Schistosomal disease require one month prior enrollment . 1 . The subject diagnose HBV HCV genotype genotype 4 /or HIV . 2 . Subjects older 50 year younger 20 year age . 3 . Women pregnant breastfeeding . 4 . Suspected hypersensitivity Interferon Ribavirin . 5 . Subjects organ transplant corneal hair transplant . 6 . Any cause liver disease base patient 's history biopsy chronic hepatitis C genotype 4 , include limited : 1 . Alpha 1antitrypsin deficiency . 2 . Wilson 's disease . 3 . Liver transplant patient . 4 . Autoimmune hepatitis . 5 . Alcoholic liver disease . 6 . Obesity induced disease . 7 . Drug relate liver disease . 8 . Coinfection Hepatitis B Virus ( HBV ) HIV ( HBsAg HIV antibodies positivity ) . 9 . Hemochromatosis ( iron deposition 2+ liver parenchyma ) 10 . Evidence advance liver disease history presence ascitis , bleed varix , spontaneous encephalopathy . 7 . In opinion investigator , subject concurrent illness disability ( exclude HCV genotype 4 ) may affect interpretation clinical efficacy and/or safety data otherwise contraindicate participation clinical study ; 1 . Unstable pulmonary , endocrine &amp; metabolic disorder e.g . poorly control diabetes . 2 . Subjects hemophilia hemoglobinopathy include limited thalassemia major minor . 3 . Bone marrow compromise contraindicate interferon treatment 4 . Central Nervous System ( CNS ) trauma active seizure require medication . 5 . The subject exhibit renal impairment evidence serum Creatinine high 2.0 mg/dL . Or history Chronic renal failure 6 . Immunologically mediate disease ( e.g . inflammatory bowel disease , idiopathic thrombocytopenic purpura , systemic lupus erythromatosis , autoimmune hemolytic anemia , scleroderma , severe psoriasis , clinical cryoglobulinemia ) 7 . Any medical condition require likely require course study , chronic systemic administration steroid . 8 . Patients clinically significant retinal abnormality . 9 . The subject history unstable deteriorate cardiac disease within previous 6 month , include , limited , follow : i. Myocardial infarction , unstable angina pectoris , coronary artery bypass surgery , coronary angioplasty ii . Congestive heart failure require hospitalization iii . Uncontrolled arrhythmias 8 . The subject diagnose major psychiatric disorder ( e.g. , major depression psychosis ) within past 2 year require hospitalization and/or involve attempted suicide . Subjects diagnose major psychiatric disorder require hospitalization involve attempt suicide must remain stable dose medication least 6 month prior screen visit . 9 . The subject history alcohol substance abuse within past 2 year . 10 . The subject positive stool sample ovum parasite ( exception : finding Entamoeba coli exclusionary ) . 11 . The subject evidence treatment malignancy ( localize basal cell cancer , squamous cell skin cancer , cancer situ resect ) within previous 5 year . 12 . The subject use investigational drug participate investigational study within 30 day screen . 13 . The subject refuse discontinue one ( ) prohibit medication least 7 day prior screen visit . 14 . The subject refuse maintain stable dose one ( ) allowable concurrent medication least 30 day prior screen visit . 15 . The subject unable unwilling follow direction . 16 . Contraindications ribavirin thus combination therapy include mark anemia , renal dysfunction , coronary artery cerebrovascular disease , inability practice birth control .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Chronic hepatitis c</keyword>
	<keyword>Egyptian population</keyword>
	<keyword>Reiferon Retard</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Nitazoxanide</keyword>
	<keyword>Bon one</keyword>
</DOC>